Palisade Bio, Inc. (PALI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Palisade Bio, Inc. (PALI) Healthcare & Pipeline Overview

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company specializing in oral therapies targeting gastrointestinal diseases. Their primary focus is LB1148, designed to protect gut integrity during intestinal stress. With a market capitalization of $358M, Palisade Bio operates in the competitive biotechnology sector, addressing unmet needs in gastrointestinal health.

What Is the Investment Thesis for PALI?

Palisade Bio, Inc. presents a focused investment opportunity within the biotechnology sector, centered on its lead candidate, LB1148. The company's strategy to address gastrointestinal mucosal barrier breakdown has the potential to tap into a significant market. A key value driver is the successful completion of ongoing clinical trials for LB1148, with positive results potentially leading to regulatory approval and subsequent commercialization. The company's current market capitalization of $358M reflects both the potential and the risks associated with clinical-stage biopharmaceutical companies. Growth catalysts include the advancement of LB1148 through clinical trial phases, potential partnerships with larger pharmaceutical companies, and expansion into new therapeutic areas within gastrointestinal health. However, potential risks include clinical trial failures, regulatory hurdles, competition from existing therapies, and the need for additional funding to support ongoing research and development. Investors should closely monitor clinical trial results and regulatory updates to assess the viability of Palisade Bio's investment potential.

Based on FMP financials and quantitative analysis

PALI Key Highlights

Lead therapeutic candidate LB1148 targets digestive enzyme activity to preserve gut integrity during intestinal stress.

• The company is focused on oral therapies, offering a potentially more convenient administration route compared to injectable alternatives.
• Founded in 2005, Palisade Bio has a history of focusing on gastrointestinal diseases and mucosal barrier protection.
• Palisade Bio operates with a relatively small team of 8 employees, indicating a lean operational structure.
• The company's beta of 1.47 suggests higher volatility compared to the overall market.

Who Are PALI's Competitors?

PALI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PALI's Key Strengths?

Focus on oral therapies for gastrointestinal diseases.

• Lead therapeutic candidate LB1148 targeting a specific unmet need.
• Experienced management team with expertise in drug development.
• Proprietary technology and intellectual property.

What Are PALI's Weaknesses?

Clinical-stage company with no commercialized products.

• Reliance on the success of LB1148.
• Limited financial resources.
• Small number of employees.

What Could Drive PALI Stock Higher?

Completion of ongoing clinical trials for LB1148.

• Potential announcement of strategic partnerships or collaborations.
• Regulatory updates regarding LB1148's approval pathway.
• Continued enrollment of patients in clinical trials.

What Are the Key Risks for PALI?

Negative return on equity (-36.8%) — the business is not currently generating profit on shareholder capital.

• Clinical trial failures or delays.
• Regulatory hurdles and rejection of LB1148.
• Competition from existing or emerging therapies.
• Need for additional funding to support research and development.
• Market volatility and investor sentiment impacting stock price.

What Are the Growth Opportunities for PALI?

• Expansion into New Therapeutic Areas: Palisade Bio has the opportunity to expand its pipeline beyond LB1148 by targeting other gastrointestinal disorders. This could involve developing therapies for conditions such as IBD, irritable bowel syndrome (IBS), or other diseases characterized by mucosal barrier dysfunction. Timeline: 3-5 years.
• Strategic Partnerships: Palisade Bio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of LB1148 and other pipeline candidates. Collaborating with established players can provide access to funding, expertise, and distribution networks, increasing the likelihood of successful market penetration. These partnerships could involve licensing agreements, co-development arrangements, or even acquisition. Timeline: 1-3 years.
• Geographic Expansion: Palisade Bio can expand its geographic reach by seeking regulatory approval and commercializing its therapies in markets outside of the United States. Europe, Asia, and other regions represent significant opportunities for growth, particularly in countries with aging populations and increasing prevalence of gastrointestinal disorders. International expansion would require navigating different regulatory landscapes and establishing local partnerships. Timeline: 3-5 years.
• Advancements in Oral Drug Delivery: Palisade Bio can leverage advancements in oral drug delivery technologies to improve the bioavailability and efficacy of its oral therapies. This could involve developing novel formulations, drug delivery systems, or encapsulation techniques to enhance drug absorption and targeting within the gastrointestinal tract. These technological advancements could provide a competitive advantage and improve patient outcomes. Timeline: Ongoing.
• Leveraging Clinical Trial Data: Palisade Bio can leverage positive clinical trial data from LB1148 to attract investment, secure partnerships, and accelerate regulatory approval. Strong clinical results demonstrating the safety and efficacy of LB1148 in protecting gut integrity would significantly enhance the company's value proposition and increase its chances of success. Effectively communicating these results to investors, regulators, and potential partners is crucial for driving growth. Timeline: Ongoing.

What Are PALI's Competitive Advantages?

• Proprietary oral formulation of LB1148.
• Patent protection for their therapies.
• Clinical trial data demonstrating efficacy.
• Focus on a specific niche within gastrointestinal health.

What Does PALI Do?

Founded in 2005 and headquartered in Carlsbad, California, Palisade Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative oral therapies. The company's mission centers on addressing serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Their lead therapeutic candidate, LB1148, is an oral liquid formulation of a digestive enzyme inhibitor. LB1148 is designed to inhibit digestive enzyme activity and preserve gut integrity during periods of intestinal stress. Such stress can result from reduced blood flow to the intestine, infections, or surgical procedures. Palisade Bio is currently focused on advancing LB1148 through clinical trials to evaluate its safety and efficacy in protecting the GI tract in various clinical settings. The company's approach targets the underlying mechanisms of GI dysfunction, aiming to improve patient outcomes and reduce the burden of GI-related complications. As a clinical-stage company, Palisade Bio does not currently have any commercialized products and relies on funding through investors and potential partnerships to support its research and development activities. The company's success is dependent on the successful completion of clinical trials and regulatory approval of LB1148.

What Products and Services Does PALI Offer?

• Develop oral therapies for gastrointestinal diseases.
• Focus on protecting the mucosal barrier of the gastrointestinal tract.
• Develop LB1148, an oral liquid formulation of a digestive enzyme inhibitor.
• Target diseases associated with the breakdown of the gut's mucosal barrier.
• Conduct clinical trials to evaluate the safety and efficacy of LB1148.
• Seek regulatory approval for their therapies from agencies like the FDA.

How Does PALI Make Money?

• Develop and patent novel oral therapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from health agencies.
• Potentially commercialize therapies directly or through partnerships.

What Industry Does PALI Operate In?

Palisade Bio operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory oversight, and substantial financial risk. The market for gastrointestinal disease therapies is substantial and growing, driven by factors such as aging populations, changing diets, and increased prevalence of chronic conditions like inflammatory bowel disease (IBD). Competition in this space includes established pharmaceutical companies and other biotechnology firms developing novel therapies. Palisade Bio's focus on mucosal barrier protection represents a targeted approach within this broader market, potentially offering a differentiated solution for patients experiencing intestinal stress.

Who Are PALI's Key Customers?

• Patients suffering from gastrointestinal diseases.
• Hospitals and healthcare providers.
• Pharmacies and distributors.

Company Profile

Palisade Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Denver, US. The company is led by CEO J. D. Finley. PALI has traded publicly since 2007.

How Palisade Bio, Inc. Is Valued

Palisade Bio, Inc. carries a market capitalization of $358M, placing it in the small-cap category. Relative to its peer group, PALI's quantitative score of 26/100 is below the peer average of 78/100.

Return on equity for Palisade Bio, Inc. stands at -36.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 23.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.0%, the inverse of the P/E and a quick read on earnings relative to price.

Palisade Bio, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 38.18 places it in the safe zone, indicating low near-term bankruptcy risk.

Palisade Bio, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.5% below estimates on average.

Wall Street analysts project Palisade Bio, Inc. revenue of about $27.9M for fiscal 2026, with EPS near $-0.24. The estimate reflects 7 contributing analysts.

PALI Financials

PALI Latest News

PALI Analyst Consensus

PALI MoonshotScore

PALI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources